Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer

F. Dexeus; C. J. Logothetis; M. L. Samuels; E. Hossan; A. C. von Eschenbach

Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer

F. Dexeus
, C. J. Logothetis
, M. L. Samuels
, E. Hossan
, A. C. von Eschenbach

Genitourinary Medical Oncology

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

Thirty-nine patients with metastatic prostate cancer refractory to hormonal manipulation were treated with vinblastine by continuous infusion. The dose was 1.5 mg/m² daily for 5 days. A 21% response rate was obtained. Eight patients, two with visceral metastasis, one with nodal disease, and five with osseous metastasis achieved objective response. The median duration of response was 28 weeks. Myelosuppression was the major side effect: the median leukocyte count nadir was 2.8 x 10³/ml and the median platelet count nadir was 184 x 10³/ml.

Original language	English (US)
Pages (from-to)	885-886
Number of pages	2
Journal	Cancer Treatment Reports
Volume	69
Issue number	7-8
State	Published - 1985

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{d143d0e1c36344b2bc14f350ee6eadcb,

title = "Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer",

abstract = "Thirty-nine patients with metastatic prostate cancer refractory to hormonal manipulation were treated with vinblastine by continuous infusion. The dose was 1.5 mg/m2 daily for 5 days. A 21\% response rate was obtained. Eight patients, two with visceral metastasis, one with nodal disease, and five with osseous metastasis achieved objective response. The median duration of response was 28 weeks. Myelosuppression was the major side effect: the median leukocyte count nadir was 2.8 x 103/ml and the median platelet count nadir was 184 x 103/ml.",

author = "F. Dexeus and Logothetis, \{C. J.\} and Samuels, \{M. L.\} and E. Hossan and \{von Eschenbach\}, \{A. C.\}",

year = "1985",

language = "English (US)",

volume = "69",

pages = "885--886",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

number = "7-8",

}

TY - JOUR

T1 - Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer

AU - Dexeus, F.

AU - Logothetis, C. J.

AU - Samuels, M. L.

AU - Hossan, E.

AU - von Eschenbach, A. C.

PY - 1985

Y1 - 1985

N2 - Thirty-nine patients with metastatic prostate cancer refractory to hormonal manipulation were treated with vinblastine by continuous infusion. The dose was 1.5 mg/m2 daily for 5 days. A 21% response rate was obtained. Eight patients, two with visceral metastasis, one with nodal disease, and five with osseous metastasis achieved objective response. The median duration of response was 28 weeks. Myelosuppression was the major side effect: the median leukocyte count nadir was 2.8 x 103/ml and the median platelet count nadir was 184 x 103/ml.

AB - Thirty-nine patients with metastatic prostate cancer refractory to hormonal manipulation were treated with vinblastine by continuous infusion. The dose was 1.5 mg/m2 daily for 5 days. A 21% response rate was obtained. Eight patients, two with visceral metastasis, one with nodal disease, and five with osseous metastasis achieved objective response. The median duration of response was 28 weeks. Myelosuppression was the major side effect: the median leukocyte count nadir was 2.8 x 103/ml and the median platelet count nadir was 184 x 103/ml.

UR - https://www.scopus.com/pages/publications/0021921166

UR - https://www.scopus.com/pages/publications/0021921166#tab=citedBy

M3 - Article

C2 - 4016795

AN - SCOPUS:0021921166

SN - 0361-5960

VL - 69

SP - 885

EP - 886

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 7-8

ER -

Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this